# Celregen Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/celregen-therapeutics

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.celregen.com
- Total disclosed funding: $20M
- Latest round: Angel (Mar 17, 2025)
- Investors on record: 2

## About

Established in 2022 and based in Hangzhou, China, Celregen Therapeutics is a medical service provider dedicated to the research and development and clinical transformation of regenerative medicine products such as cornea and pancreatic islets. The company was incubated by the New Drug Innovation Fund of Fujian Capital. It has a research and development center in Shanghai. In March 2025, it raised approximately CNY 100 million in angel+ funding from returning investors Shanghai Creation Investment and Fosun Health Capital. 

The company is committed to the innovation of stem cell regenerative medicine technology and the research and development of iPSC organ transplantation alternative products. Its products include the CRG-101 iPSC-derived corneal endothelial cell product pipeline and the CRG-002 iPSC-derived pancreatic islet cell pipeline. It has also established three iPSC regenerative medicine technology platforms, namely the CRG-iPSC somatic cell reprogramming platform, the CRG-EDIT gene editing platform, and the CRG-XDIF stem cell multidirectional differentiation platform.

The company generates revenue by providing cornea, pancreatic islets, liver and gallbladder cell regeneration medicine products.

The company will use the funds to build an iPSC regenerative medicine platform and promote clinical transformation in pipelines such as metabolism and ophthalmology.

## Funding rounds

- Angel, Mar 17, 2025, $14M — Shanghai Creation Investment, Fosun Health Capital
- Angel, Sep 14, 2024 — Shanghai Creation Investment, Fosun Health Capital
- Seed, Aug 6, 2022, $6.7M — Fosun Health Capital

## Investors

- Fosun Health Capital (https://capitalatlas.ai/funds/fosun-health-capital) — Seed, Angel
- Shanghai Creation Investment (https://capitalatlas.ai/funds/shanghai-creation-investment) — Angel